ABSTRACT
@#During chemotherapy of malignant tumors,neutropenia is the most important adverse event caused by myelosuppressive chemotherapeutics,of which the degree and duration are closely related to the risk of infection and even death.Granulocyte-colony stimulating factor(G-CSF) is an endogenous hematopoietic growth factor that can stimulate the proliferation and differentiation of neutrophil precursors,and increase the survival rate and activity of mature neutrophils.Recombinant human granulocyte-colony stimulating factor(rhG-CSF) is an artificially synthesized cytokine with G-CSF biological activity.It is used clinically for the prevention and treatment of neutropenia after treatment with cytotoxic chemotherapeutics,requiring multiple medications and repeated injections during application for its short half-life.Pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF) is its long-acting dosage form,and patients only need to be administered once per cycle of chemotherapy,which has been widely used in clinical practice because of its stability and convenience.This paper systematically described the clinical application value of PEG-rhG-CSF in neutropenia after chemotherapy,aiming to provide a reference for its further clinical application.
ABSTRACT
Objective:To evaluate the effect of preventive application of PEG-rhG-CSF on the prevention of neutropenia during concurrent chemoradiotherapy in patients with lung cancer.Methods:A total of 149 patients with lung cancer who received concurrent chemoradiotherapy at Peking University Cancer Hospital from April 2020 to April 2021 were retrospectively analyzed. There were 79 cases in the prevention group, including 48 cases of primary prevention group (preventive application of PEG-rhG-CSF in all concurrent chemoradiotherapy cycles) and 31 cases of secondary prevention group (preventive application of PEG-rhG-CSF in the concurrent chemoradiotherapy cycles after neutropenia occurred). There were 70 cases in non-prevention group. The incidence of grade 3-4 neutropenia, the completion rate of concurrent chemoradiotherapy, the rate of chemoradiotherapy dose reduction and treatment delay, and the rate of hematological toxicities related hospitalization were compared between the prevention group and the non-prevention group.Results:The incidence of grade 3-4 neutropenia in the whole group was 32.2% (48/149), including 6.3% (3/48) in the primary prevention group, 9.7% (3/31) in the secondary prevention group, and 35.7% (25/70) in the non-prevention group. The difference was statistically significant ( χ2=17.81, P<0.001) in the incidence of grade 3-4 neutropenia. The incidence of febrile neutropenia was 3.4% (5/149) in the whole group, but none of them occurred in the primary prevention group. The full completion rate of concurrent chemotherapy was 96.2% (76/79) in the prevention group, which was significantly higher than 82.9% (58/70) in the non-prevention group ( χ2=7.30, P=0.007). The incidence of treatment delayed and dose reduction of chemoradiotherapy was 19.0% (15/79) in the prevention group and 40.0% (28/70) in the non-prevention group, and the difference was statistically significant ( χ2=7.98, P=0.005). Conclusions:The preventive application of PEG-rhG-CSF can effectively reduce the incidence of neutropenia and better ensure the concurrent chemoradiotherapy in lung cancer patients on schedule.
ABSTRACT
Objective To explore the efficacy and safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing chemotherapy-induced neutropenia in locally advanced non small cell lung cancer (NSCLC) patients at nutritional risk. Methods A total of 337 locally advanced NSCLC patients at nutritional risk were selected. They were randomly divided into three groups: 112 cases in the non-prophylactic drug group (control group), 112 cases in the prophylactic use of rhG-CSF treatment group (rhG-CSF group), and 113 cases in the prophylactic use of PEG-rhG-CSF treatment group (PEG-rhG-CSF group). The incidence and duration of neutropenia after chemotherapy and the ratio of CD4+/CD8+T cells in peripheral blood were observed. Results The incidences of neutropenia in the control group, rhG-CSF group, and PEG-rhG-CSF group were 67.97%, 41.57%, and 38.98% (P < 0.05), respectively. The incidences of grade Ⅲ-Ⅳ neutropenia in the three groups were 22.39%, 14.25%, and 11.14% (P < 0.05); moreover, the incidence of febrile neutropenia in the three groups was 3.55%, 1.84%, and 1.21% (P < 0.05); in addition, the ratios of CD4+/CD8+T cells in peripheral blood were 1.27±0.44, 1.41±0.52, and 1.49±0.42 (P < 0.05). The duration of grade Ⅲ-Ⅳ neutropenia and the time required for the neutrophil value to reach 2.0×109/L from the lowest value in the PEG-rhG-CSF group were lower than those in the control and rhG-CSF groups (P < 0.05). Conclusion The PEG-rhG-CSF preventive treatment used in the course of chemoradiotherapy in locally advanced NSCLC patients at nutritional risk can reduce the incidence of neutropenia and improve immunologic function. PEG-rhG-CSF preventive treatment is worthy of clinical recommendation.
ABSTRACT
Objective: To analyze the clinical effect of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) after chemotherapy in patients with soft tissue sarcoma. Methods: The clinical data of the patients with soft tissue sarcoma who were diagnosed in the Oncology Department of Zhongshan Hospital Affiliated to Fudan Universtiy from July 2016 to July 2019, and received the preventive treatment of PEG-rhG-CSF after chemotherapy to prevent the increase of leukocyte count in vivo, was collected and analyzed. Results: A total of 107 patients with soft tissue sarcoma were treated with PEG-rhG-CSF after chemotherapy. The incidence of neutropenia was 48.6% (52/107), in which the incidence of grade 3-4 neutropenia was 28.0% (30/107), and the incidence of febrile neutropenia (FN) was 4.7% (5/107). The incidence of neutropenia in male or female patients was 52.8% (28/53) or 44.4% (24/54), respectively; there was no significant difference (P > 0.05). The incidence of neutropenia in elderly patients (≥ 65 years old) or young and mid-aged patients ( 0.05). The use of IA chemotherapy with ifosfamide and doxorubicin was more toxic, the incidence of neutropenia was 50.9% (27/53) with 4 cases of FN. In the patients who received major surgery (grade 3-4) or those who did not receive major surgery (grade 1-2 and no surgery), the incidence of neutropenia was 60.0% (36/60) or 34.0% (16/47), respectively; there was significant difference (P < 0.05). In the patients who received radiotherapy or those without radiotherapy, the incidence of neutropenia was 70.0% (14/20) or 43.7% (38/87), respectively; there was significant difference (P < 0.05). Conclusion: The prophylactic use of PEG-rhG-CSF can avoid severe myelotoxicity in the majority of patients with soft tissue sarcoma. However, the risk of neutropenia is still high in the patients who received chemotherapy based on ifosfamide and anthracyclines, as well as in the patients who have received radiotherapy and major surgery in the past. All these are worthy of concern.
ABSTRACT
Objective: To evaluate the efficacy and safety of PEG-rhG-CSF therapy in the primary and secondary prevention of chemo-therapy-induced neutropenia . Methods: This single-center, one-arm, and open-label clinical study involved 217 patients with non-my-eloid malignant tumors. These patients included 18 gynecologic oncology (3 endometrial and 15 ovarian cancer), 50 breast cancer, 30 bone tumor, and 119 lymphoma patients who underwent a total of 774 cycles of chemotherapy, comprising 146 primary and 71 sec-ondary prevention patients. The patients ≥45 kg and those <45 kg received a single subcutaneous injection of 6 mg and 3 mg PEG-rhG-CSF, respectively, 24-48 h after the chemotherapy was completed. All patients received only one dose of PEG-rhG-CSF admin-istration per chemotherapy cycle. Results: The overall incidence of febrile neutropenia (FN) was found to be 5.7%, with rates of 4.9% and 7.2% in the primary and secondary prevention groups, respectively. Univariate and multivariate Logistic regression analyses re-vealed that the longer PEG-rhG-CSF was sustained in the treatment cycle, the lower the incidence of FN was. The incidence of FN was significantly lower in the second cycle of the treatment than in the first in both the primary and secondary prevention groups (cycle 1 vs. cycle 2: 11.6% vs. 4.4%, respectively, P=0.039, in the primary group; 16.9% vs. 5.6%, respectively, P=0.034, in the secondary group). The overall incidence of gradeⅣneutropenia was 10.3% (80/774), with rates of 6.7% (34/510) and 17.4% (46/264) in the primary and secondary prevention groups, respectively (P<0.001). The incidence of gradeⅣneutropenia was significantly lower in the second cy-cle of the treatment than in the first (cycle 1 vs. cycle 2: 17.1% vs. 5.3%, respectively, P=0.004, in the primary group; 46.5% vs. 11.3%, respectively, P<0.001, in the secondary group). The treatment-induced toxicity mainly involved bone pain, with 3.7% (8/217) and 1.8% (4/217) incidence rates for grade 1-2 and 3-4 bone pain, respectively. Conclusions: PEG-rhG-CSF administration can effectively reduce the incidence of FN (5.7%) when prophylactically applied to patients with non-myeloid malignant tumors. Primary prevention can sig- nificantly reduce the risk of grade IV neutropenia in all chemotherapy cycles relative to the secondary prevention.
ABSTRACT
Objective To study and analyze the clinical effects of rhG-CSF combined with chemotherapy in the treatment of acute leukemia. Methods 60 patients with acute leukemia were selected as the study subjects (from February 2015 to April 2017). The control group was given routine chemotherapy, the experimental group was given rhG-CSF on the basis treatment of the control group. Clinical indicators of two groups of patients were compared and analyzed. Results After the corresponding treatment, the effective rate was 63.3% in the experimental group and 43.3% in the control group, and the difference was statistically significant (P<0.05). After treatment, the quality of life score of the control group (62.30±9.20) was significantly lower than the experimental group (76.88±10.90) with statistical difference (P<0.05). The number of neutrophils reduced from 0.1×109/L to 1.5×109/L in the experimental group took (11.23±1.65), and the time for the control group was (18.90±2.78), and the difference between the two groups was statistically significant (P<0.05). There were no serious adverse reactions in the two groups, and the incidence was 10% and 13.3%, which was not statistically significant. Conclusion rhG-CSF combined with chemotherapy in the treatment of acute leukemia has good clinical effect.
ABSTRACT
Objective To study and analyze the clinical effects of rhG-CSF combined with chemotherapy in the treatment of acute leukemia. Methods 60 patients with acute leukemia were selected as the study subjects (from February 2015 to April 2017). The control group was given routine chemotherapy, the experimental group was given rhG-CSF on the basis treatment of the control group. Clinical indicators of two groups of patients were compared and analyzed. Results After the corresponding treatment, the effective rate was 63.3% in the experimental group and 43.3% in the control group, and the difference was statistically significant (P<0.05). After treatment, the quality of life score of the control group (62.30±9.20) was significantly lower than the experimental group (76.88±10.90) with statistical difference (P<0.05). The number of neutrophils reduced from 0.1×109/L to 1.5×109/L in the experimental group took (11.23±1.65), and the time for the control group was (18.90±2.78), and the difference between the two groups was statistically significant (P<0.05). There were no serious adverse reactions in the two groups, and the incidence was 10% and 13.3%, which was not statistically significant. Conclusion rhG-CSF combined with chemotherapy in the treatment of acute leukemia has good clinical effect.
ABSTRACT
Objectivc To observe the therapeutic effects of combined cytokines on hematopoietic injuries induced by 4.5 Gy60 Co γ-rays irradiation in beagles,and to provide experimental evidences for the clinical treatment of extremely severe myeloid acute radiation sickness(ARS).Methods 16 beagles were given 4.5 Gy60 Co γ-rays total body irradiation,and then randomly assigned into irradiation control group,supportive care group and cytokines group.In addition to supportive care,recombinant human granulocyte colony-stimulating factor (rhG-CSF),recombinant human interleukin-11(rhIL-11)and recombinant human interleukin-2(rhIL-2)were administered subcutaneouly to dogs in cytokines group.Peripheral blood hemogram was examined once every two days.Bone marrow and peripheral blood were collected to proceed colony cultivation 4 d pre-irradiation and 1 and 45 d post-irradiation.Conventional histopathological sections of sternum were prepared to observe the histomorphology changes. Results After irradiation,the population of all kinds of cells in peripheral blood declined sharply.WBC nadir Was elevated(1.04×109/L,but 0.28×109/L and 0.68×109/L for the irradiation control group and the supportive care group separately),the duration of thrombocytopenia was shortened (24 days,but 33 days for the supportive care groug) and red blood cell counts were maintained in the range of normal values after cytokincs treatment in combination.The colony forming efficiency of haemopoietic stem cells(HSCs)in bone marrow and peripheral blood decreased obviously 1 d post irradiation,but recovered to the level of that before irradiation 45 d post irradiation after supportive care and cytokines treatment.Hematopoietic cells disappeared in bone marrow of animals in irradiation control group,but hematopoietic functions were recovered after cytokines were administrated.Conclusions RhG-CSF.rhIL-11 and rhIL-2 used in combination could elevate WBC nadir,accelerate the recovery of leukocytes,platelets and red blood cells and promote the proliferation,differentiation and maturity of HSPCs left in the body after 4.5 Gy γ-rays total body irradiation,eventually restore the hematopoietic function.Hence,combination of rhG-CSF,rhIL-11 and rhIL-2 could serve as better therapeutic strategy to treat extremely severe myeloid ARS.
ABSTRACT
Objective To explore the protective effect of rhG-CSF given intranasally on cerebral infarct rats by observing the neurological dysfunction and the expression of Fas ligand (FasL) in hippocampus of cerebral infarct rats.Methods Middle cerebral artery occlusion(MCAO) model rats were established by nylon strand,reperfuse 2 hours later,and give rhG-CSF through subcutaneous and intranasal way.The rats were divided into the nermal group,the sham-operated control group(sham),MCAO group,MCAO+NS given intranasally group(NS),MCAO + rhG-CSF given subcutaneously group,and MCAO + rhG-CSF given intranasally group each group had 6 rats. At the time of 3d after reperfusion,neurological severity scores (NSS) test was performed and the expression of FasL was detected via immunohistochemical staining in collateral hippocampus. Results Neurological dysfunction appeared in all groups except for the normal and the sham group. The dysfunction of the MCAO and the NS group was the most serious,the NSS was the highest(10.20±1.85,10.30±1.76),the number of FasL positive cells was the most(41.17±3.25,41.00±2.76),and there was no obvious difference between the two groups ( P ＞0.05);the NSS and FasL positive cells decreased in the subcutaneous group(5.67±1.32,P ＜0.01;32.67±1.97,P ＜0.01) and decreased further more in the intranasal group(4.00±0.93,P ＜0.05;19.50±1.05,P ＜0.01).Conclusions rhG-CSF given intranasally can relieve the neurological dysfunction of cerebral infarct rats,and brain cells are thereby protected by resisting the expression of FasL.
ABSTRACT
Objective To explore the therapeutic effect of rhIL-11 and rhG-CSF on mouse bone marrow injury induced by neutron irradiation.Methods 130 male BALB/c mice were irradiated by 3.0 Gy neutron and mice peripheral blood cells,bone marrow pathological changes,bone marrow nucleated cell counts,AgNOR content,apoptosis and necrosis rates and Bax protein content were observed by means of blood cells automatic analyzer,HE staining,AgNOR staining,flow cytometry,immunohistochemistry staining and image analysis.Results In the irradiation group and the rhIL-11 group,the mice peripheral blood white blood cells,bone marrow nucleated cell counts and AgNOR content was decreased progressively.The Bax protein was positively or strongly positively expressed in the cytoplasm of the hematopoietic cells and the Bax protein content was increased progressively at 6 h,1 d,3 d after irradiation.In the irradiation group,the rates of apoptosis and necrosis in the mice hematopoietic cells were greatly increased and that of necrosis was significant at 6 h after irradiation.In the rhIL-11 + rhG-CSF group,the counts of bone marrow nucleated cell and AgNOR were increased and the Bax protein content was decreased at 3 d after irradiation,while in the rhIL-11 group,the indexes mentioned above were not obviously different compared with those of the irradiation group.Conclusions The mice bone marrow hematopoietic function is seriously damaged by 3.0 Gy neutron irradiation,rhIL-11 and rhG-CSF could improve the mice hernatopoietic function after neutron irradiation,and combination of them is more effective to stimulate the hematopoitic function than either of them alone.
ABSTRACT
Background and purpose:Recombinant human granulocyte colony-stimulating factor(rhG-CSF)is a kind of polypeptide.It can stimulate the haemopoietic stem cell and granule progenitor cell to differentiate and proliferate.The neutrophil can be accelerated to release and promote its function of phagocytosis,chemotaxis and oxidative burst by rhG-CSF.In this study,we aimed to explore the effect of rhG-CSF on morphology、phenotype and function of neutrophil in patients with malignant lymphoma after treatment of chemotherapy.Methods:White blood cell(WBC) was counted by the method of COULTER.The morphology of neutrophil was observed on Wright's-stained peripheral blood smear.The phagocytotic function and chemotaxis of neutrophil were assessed by either measuring the amount of hydrogen peroxide or by the agarose method.Oxidative burst and phenotype of neutrophil was analysed by flow cytometry using immunofluorescence technique.Results:①There was Hypogranular in some neutrophilic cytoplasm after chemotherapy,the number of "toxic" granulation,vacuoles and Dohle bodies increased from 5.4%,3.2%,0.5% to 55.0%,11.8%,4.1% in neutrophils from patients with malignant lymphoma after rhG-CSF administration,.②Compared to normal control,5.76?mol/LH_(2)O_(2).10~(-6)PMN,1.85,76.4,the neutrophil functions of phagocytosis,chemotaxis,oxidative burst were impaired after chemotherapy 2.73?mol/LH_(2)O_(2).10~(-6)PMN,0.97,51.8%,rhG-CSF increased the function,7.02?mol/LH_(2)O_(2).10~(-6)PMN,1.89,78.4%,the neutrophil function from these patients had returned to normal or were even exceeded.③ A mild increase of CD64 expression from 5.4%,3.2%,0.5% and a significant decrease of CD62L expression from 7.47% to 3.95% were found in patients after rhG-CSF treatment.No changes of CD16,CD32,CD14 and CD11b expression were detected in these patients before or after G-CSF administration.Conclusions:rhG-CSF administration can modify the morphology,phenotypeand partially recover the impaired function of neutrophil from the patients with Malignant Lymphoma after chemotherapy,andit may improve anti-infection ability of the human body.
ABSTRACT
Objective To study the impact on the proliferation and cytotoxicity of donor T cells during mobilization with rhG - CSF. Methods The peripheral blood mononuclear cells (PBMNC) were collected from 20 healthy donors before mobilization and on the fifth day of mobilization with rhG - CSF. After the PBMNC was activated with 500 ng/ml of CD3 monoclonal antibody and 500 ?g/ml of rhIL -2 for 96 hours,the activated T cells were collected for testing proliferation, cytotoxicity. Fas expression, perforin and Fas ligand (FasL) mRNA expression,and IFN -? concentration in the culture medium of the activated T cells, were determined by radioimmunoassay. Results The proliferation activity and cytotoxicity of T cells activated with CD3 monoclonal antibody and rhIL - 2 were reduced markedly after mobilization with rhG - CSF(P0.05). The activated T cells expressed perforin mRNA and didn' t express FasL mRNA both before and after mobilization with rhG - CSF. The concentration of IFN -? in the culture medium of the activated T cells decreased significantly after mobilization with rhG - CSF(P
ABSTRACT
Objective To investigate the blood cell separator collection of peripheral blood stem cell after using recombinant human granulocyte colony - stimulating factor (rhG - CSF) to mobilize the normal donor and patients with hematologic malignancies, through morphological observation of lymphocyte ratios and PBSC vitality of mononuclear cells. Methods Peripheral blood mononuclear cells (MNC)were collected from 15 cases of healthy donors and 14 patients of hematologic malignancies with rhG - CSF mobilization dose with blood cell separators. The number of nucleated cells, classification of nucleated cells, MNC count and cell viability were observed. Results ①The total number of nucleated cells in normal donor group was(4.31?1.41)?10~8 / kg,and hematologic malignancies group was (6.21?4.37)?10~8/kg. ②The number of nucleated cells of PBSC in hematologic malignancies group was higher than those of the donor group (P0.05).④MNC number was (96.7? 5.1) % in normal donor group counts, and in which lymphocytes was (65.9?9.4)% , myeloid (16.3?8.7)% , mononuclear cells (16.5?4.0)% ,respectively,MNC number was (92.7?15.6)% in hematologic malignancies group, and in which lymphocytes was (55.3?16.7)% , myeloid (24.3?16.5) % , mononuclear cells (14.9?9.1)%, respectively. ⑤Cell viability in normal donor group before and after cryopreservation were (91.5?4.3)%, (67.4?9.1) % , in hematologic malignancies grou were (82.9?11.1) % , (56.5?20.1) % , respectively. Cell viability was significantly different (P
ABSTRACT
0.05). But in repeated chemotherapy, the period of leukopenia recovered to normal was shorter in group B than that in group A or group C. The effects of the domestic rhG-CSF on leu-copenia induced by chemotherapy were similar to the imported products of same dose. CONCLUSION: Low dose of domestic rhG-CSF (75?g) can effectively treat the leukopenia caused by postchemotherapy in patients with gynecological tumors. 150?g of domestic rhG-CSF is more effective than 75?g of domestic or import rhG-CSF in treating leukopenia in repeated chemotherapy.
ABSTRACT
PURPOSE: This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML). MATERIALS AND METHODS: After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days. RESULTS: The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%). CONCLUSION: The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.
Subject(s)
Humans , Cytarabine , Drug Therapy , Granulocyte Colony-Stimulating Factor , Granulocytes , Headache , Idarubicin , Leukemia, Myeloid, Acute , Neutropenia , Neutrophils , Remission InductionABSTRACT
Objective To evaluate the effects of recombinant human hematopoietic synergistic factor (rhHSF) on rapid mobilization of the peripheral blood stem cells. Methods 8 monkeys were divided into rhG-CSF 10?g/(kg?day) and rhG-CSF 10?g/(kg?day) + rhHSF 500?g/(kg?day) group, with 4 monkeys in each group. All of them received rhG-CSF subcutaneously once daily for 4 days, and in the latter group, the animals received rhHSF subcutaneously in single dose on the fifth day. Results The highest counts of CD34~+ cell, CFU-GM and neutrophils in animals receiving rhHSF only were 23, 1.8 and 3.3 times of baseline value at 180, 45 and 60 min, while those in animals receiving rhG-CSF and rhHSF were 41.3, 8.3 and 4.9 times of base line value. Conclusion rhHSF can rapidly mobilize hematopoietic stem cells and neutrophils into peripheral blood, and it is found to synergize with G-CSF to augment stem cell mobilization, suggesting a potent clinical utility of rhHSF in peripheral blood stem cells transplantation.
ABSTRACT
To evaluate the effects of recombinant human stem cell factor on mobilization of peripheral blood stem cells, 30 monkeys were divided into control, rhG CSF 10?g?kg -1 ?d -1 (?KD), rhSCF 50?KD, rhG CSF 10?KD+rhSCF 20?KD, rhG CSF 10?KD+rhSCF 50?KD and rhG CSF 10?KD+rhSCF 125?KD groups. The monkeys were given subcutaneous injections of rhSCF for 8 days and/or rhG CSF for 5 days. The highest value of leukocyte in rhG CSF and rhSCF groups was 206% and 200% respectively, and that of rhG CSF+rhSCF groups was 280% to 310%. CFU GM of peripheral blood was up to 1 1, 1 3 and 5 8～7 9 times respectively after the mobilization. CD34 positive cell number of joint mobilization group was 20, 24 and 35 times respectively of that before mobilization. rhSCF can mobilize the effect of peripheral blood stem cells, and the effect of joint rhSCF+rhG CSF is better.
ABSTRACT
PURPOSE: Receptors for the Fc of IgG(FcvR) and a beta2 integrin molecule, CD11c/CD18 are important in clearance of microbes by granulocytes. We performed an in vitro study on the effect of recombinant human granulocyte colony-stimulating factor(rhG-CSF), or granulocyte-macrophage colony-stimulating factor(rhGM-CSF) on the expression of Fc R II, Fc R III, CD11c and CD18 and respiratory burst function of granulocytes. METHODS: Peripheral blood was collected from six healthy adults. The isolated granulocytes were stimulated with rhG-CSF, 250mg/mL, rhGM-CSF, 100ng/mL or both of them for 1, 3, 9, 24, and 48 hours. Using flow cytometry, we compared the expression of the Fc R II, Fc R III, CD11c and CD18 of granulocytes before and after stimulation. We also the studied respiratory burst of granulocytes with chemiluminescence assay. RESULTS: Fc R II and CD18 expression were not changed significantly after stimulation. Fc R III expression was decreased significantly after stimulation with rhG-CSF, rhGM-CSF, or both of them. CD11c expression was increased initially but was found to decrease significantly after 9 hours of stimulation. Granulocytes treated with rhG-CSF, rhGM-CSF, or both displayed enhanced respiratory burst. Our results suggest that exposure of granulocyte to growth factor results in granulocyte activation. CONCLUSION: We have shown that rhG-CSF and rhGM-CSF resulted in an activation of peripheral blood granulocytes immunophenotypically and functionally.
Subject(s)
Adult , Humans , CD18 Antigens , Flow Cytometry , Granulocytes , Luminescence , Receptors, IgG , Respiratory BurstABSTRACT
20?10 6/L were observed in the blood. No patients presented bone pain, fever, abnormal function of liver and kidney, and so on. Conclusions:Our results indicated that rhG-CSF is efficacious and safe in auto-PBSCT for patients with plasma cell diseases. Therefore, the expense of hospitalization would be reduced significantly.
ABSTRACT
PURPOSE: Current intensive anticancer therapy may cause myelosuppression with an increased risk of severe infections. As a result, the administration of chemotherapy in cancer patients might be delayed often. Hemopoietic growth factors, which are responsible for the differentiation and functional regulation of granulocytes and monocytes, have been cloned and are available as rhG-CSF and rhGM-CSF. The aim of this study was to compare the efficacy and side effects of rhG-CSF and rhGM-CSF in children with cancer who received chemotherapy. METHODS: The study included 55 children ranging in age from 2 to 18 years who received chemotherapy for cancer and had absolute neutrophil count (ANC) under 500/muL. The growth-factors were administered subcutaneously starting in doses of 5~10 mug/ kg/day. The ANC was determined by complete blood counts starting on the first day of administration and every other day thereafter until the ANC rose above 1,000/muL. RESULTS: There was no significant difference in the mean days for increase of the mean ANC value >500/muL (5.0+/-2.9 vs 5.7+/-4.2 days) and >1,000/muL (5.9+/-3.2 vs 6.4+/-4.8 days) after rhG-CSF and rhGM-CSF respectively. Side effects of rhG-CSF and rhGM-CSF were fever, myalgia, bone pain, elevation of ALT and rGT and abdominal pain in order and there was no difference between two growth factors. Also the numbers of transfusion of packed RBCs (0.7+/-0.8 vs 0.7+/-0.8) and platelets (0.8+/-1.0 vs 0.6+/-0.9) were not different after the two growth factors. CONCLUSION: It seems to be that rhG-CSF and rhGM-CSF are comparable in clinical effects and side effects when used for granulocytopenia in children with cancer.